MINERALYS THERAPEUTICS INC. - COMMON STOCK

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

07 May 2025 08:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

05 May 2025 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

23 Apr 2025 17:23:03 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)

29 Mar 2025 14:30:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

25 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

18 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo

17 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

11 Mar 2025 22:20:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

10 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

10 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

07 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

12 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

05 Feb 2025 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria

04 Feb 2025 08:00:01 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension

08 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

11 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

05 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

04 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

30 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024

22 Oct 2024 08:00:00 By Nasdaq GlobeNewswire